We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

171 hedge funds and large institutions have $540M invested in Eagle Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 66 increasing their positions, 54 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,306% more call options, than puts

Call options by funds: $1.34M | Put options by funds: $16K

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

22% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 54

4% more funds holding

Funds holding: 164 → 171 (+7)

15% less capital invested

Capital invested by funds: $633M → $540M (-$92.7M)

Holders
171
Holders Change
+7
Holders Change %
+4.27%
% of All Funds
3.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
66
Reduced
54
Closed
18
Calls
$1.34M
Puts
$16K
Net Calls
+$1.33M
Net Calls Change
+$734K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$17.1M
2
BlackRock
BlackRock
New York
+$7.8M
3
BIP
Brandes Investment Partners
California
+$6.47M
4
Citadel Advisors
Citadel Advisors
Florida
+$5.6M
5
Morgan Stanley
Morgan Stanley
New York
+$5.06M

Top Sellers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
-$21.2M
2
CS
Credit Suisse
Switzerland
-$17.2M
3
TCM
Tang Capital Management
California
-$8.46M
4
LSV Asset Management
LSV Asset Management
Illinois
-$6.77M
5
WG
Winton Group
United Kingdom
-$3.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
176
Systematic Financial Management
New Jersey
– -$318K -6,635 Closed
GAM
177
Gotham Asset Management
New York
– -$254K -5,304 Closed
Connor, Clark & Lunn Investment Management (CC&L)
178
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$252K -5,251 Closed
GC
179
Guggenheim Capital
Illinois
– -$207K -4,319 Closed
LIA
180
LS Investment Advisors
Michigan
– -$108K -2,255 Closed
Canada Pension Plan Investment Board
181
Canada Pension Plan Investment Board
Ontario, Canada
– -$34K -700 Closed
PCG
182
Private Capital Group
Connecticut
– -$6K -125 Closed
CFG
183
Citizens Financial Group
Rhode Island
– -$5K -101 Closed
1IA
184
1834 Investment Advisors
Wisconsin
– -$2K -42 Closed
OPS
185
Orion Portfolio Solutions
Nebraska
– -$1K -16 Closed
Rockefeller Capital Management
186
Rockefeller Capital Management
New York
– -$1K -16 Closed
PFGIA
187
Patriot Financial Group Insurance Agency
Massachusetts
– +$219 +5 New
ASN
188
Advisory Services Network
Georgia
– +$350 +8 New
4 5 6 7
8

EGRX Hedge Fund Activity: Q3 2020 in Review

171 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2020, worth a combined $540M — down 15% from $633M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new EGRX positions and 18 closed out — a net gain of 8 holders — while 66 added to existing stakes and 54 trimmed.

The largest buyer was Armistice Capital, adding an estimated $17.1M. The largest seller was Park West Asset Management, cutting an estimated $21.2M.

  • 171 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2020, up from 164 in Q2 2020.
  • Funds reported $540M of Eagle Pharmaceuticals, Inc. stock for Q3 2020, down 15% quarter-over-quarter.
  • 26 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2020 and 18 closed out, a net change of +8 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2020 was Armistice Capital, an estimated $17.1M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q3 2020 was Park West Asset Management, an estimated $21.2M sold.

Based on aggregated 13F filings for Q3 2020.